The present invention relates to methods for reprogramming somatic cells into pluripotent stem cell-like cells. Such cells may express pluripotency inducing genes including Oct4, Nanog and Sox2 without introducing exogeneous genes, proteins, or chemicals. The discovery that the inhibition of mechanosensitive and stretch-activated ion channels in somatic cells specifically activates pluripotency inducing factor genes inspired the cell reprogramming culture methods in which somatic cells were incubated with the inhibitor, GsMTX4, against mechanosensitive and stretch-activated ion channels, cultured on the soft hydrogel surface, or treated with cholesterol depletion substance, methyl-beta-cyclodextrin (MβCD). Described methods produce pluripotent stem cell-like cells and subsequently re-differentiated cells, which include adipocytes, osteocytes, neuronal cells. Methods may be combined to increase the efficiency of the somatic cell reprogramming A somatic cell reprogramming kit was also created with tissue culture dishes casted with hydrogel (dehydrated) and MβCD.

A biological library that includes a plurality of cryo-silicified cells, a plurality of dehydrated cryo-silicified cells, or both, where the cryo-silicified cells and/or the dehydrated cryo-silicified cells contain accessible biological information. In some embodiments, the biological information includes genetic information, proteomic information, or transcriptomic information. Members of the library may be analyzed to identify changes in the biological information associated with a medical condition or response to treatment. When the library includes B lymphocytes, cellular material from the B lymphocytes may be used to produce an antibody.

A biological library that includes a plurality of cryo-silicified cells, a plurality of dehydrated cryo-silicified cells, or both, where the cryo-silicified cells and/or the dehydrated cryo-silicified cells contain accessible biological information. In some embodiments, the biological information includes genetic information, proteomic information, or transcriptomic information. Members of the library may be analyzed to identify changes in the biological information associated with a medical condition or response to treatment. When the library includes B lymphocytes, cellular material from the B lymphocytes may be used to produce an antibody.

The present application relates to fibers having a diameter of 1 nm to 10,000 nm, of one or more biocompatible polymers, wherein the polymers have a backbone which includes a positively charged component from a zwitterionic moiety. Additionally, this application discloses an implantable therapeutic delivery system and its method of formation, comprising a housing defining a chamber, wherein said housing is porous and formed from the fibers. Inside of the housing includes a preparation of cells which release a therapeutic agent from the chamber. The implantable therapeutic delivery system can be used in the treatment of diabetes.

Disclosed herein are methods for generating satellite cells and compositions including satellite cells.

Disclosed herein are methods for generating satellite cells and compositions including satellite cells.

The present invention provides various compositions and methods useful for the treatment of pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), and methods for activating pancreatic tissue-specific anti-tumor T cell immunity. In some embodiments such methods involve administration of IL33. In some embodiments such methods involve administration of a PD-1 and/or PD-L1 inhibitor.

The present invention provides various compositions and methods useful for the treatment of pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), and methods for activating pancreatic tissue-specific anti-tumor T cell immunity. In some embodiments such methods involve administration of IL33. In some embodiments such methods involve administration of a PD-1 and/or PD-L1 inhibitor.

The present invention provides methods of treating, preventing or delaying the progress of cancer and/or tumour in a subject comprising administering to the subject a treatment regimen comprising an effective amount of a PD-1 axis binding antagonist and a population of modified immunoresponsive cells expressing or presenting a heterologous TCR. The invention also provides methods of enhancing immune function in a subject having cancer and/or tumour comprising administering to the subject a treatment regimen comprising an effective amount of a PD-1 axis binding antagonist and a population of modified immunoresponsive cells expressing or presenting a heterologous TCR.

The present invention provides methods of treating, preventing or delaying the progress of cancer and/or tumour in a subject comprising administering to the subject a treatment regimen comprising an effective amount of a PD-1 axis binding antagonist and a population of modified immunoresponsive cells expressing or presenting a heterologous TCR. The invention also provides methods of enhancing immune function in a subject having cancer and/or tumour comprising administering to the subject a treatment regimen comprising an effective amount of a PD-1 axis binding antagonist and a population of modified immunoresponsive cells expressing or presenting a heterologous TCR.